跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
DYRK1A
首页
药物
DYRK1A
DYRK1A
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF
EP 3943086 A1
申请人: BIOSPLICE THERAPEUTICS INC
优先权: 2016
CN
EP
US
7 件公开
4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF
EP 4543886 A1
申请人: BIOSPLICE THERAPEUTICS INC
优先权: 2022
CN
EP
US
WO
6 件公开
US 20250206746 A1
申请人: BIOSPLICE THERAPEUTICS INC
优先权: 2023
CN
US
WO
3 件公开
SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF
EP 4543888 A4
申请人: UNIV ARIZONA
优先权: 2022
EP
US
WO
6 件公开
US 12528810 B2
申请人: UNIV ARIZONA
优先权: 2019
US
SMALL MOLECULE INHIBITORS OF DYRK1/CLK AND USES THEREOF
EP 3856186 A4
申请人: UNIV ARIZONA
优先权: 2018
CN
EP
US
WO
5 件公开
WO 2026096717 A1
申请人: UNIV ARIZONA
优先权: 2024
WO
Imidazolone derivatives as inhibitors of protein kinases in particular DYRK1A, CLK1 and/or CLK4
US 12398129 B2
申请人: PERHA PHARMACEUTICALS
优先权: 2020
CN
EP
US
WO
5 件公开
EP 4173675 A1
申请人: PERHA PHARMACEUTICALS
优先权: 2021
CN
EP
US
WO
5 件公开
EP 4173674 A1
申请人: PERHA PHARMACEUTICALS
优先权: 2021
CN
EP
US
3 件公开
EP 4173673 A1
申请人: PERHA PHARMACEUTICALS
优先权: 2021
CN
EP
2 件公开
NUCLEOSIDE DERIVATIVE HAVING MULTI-TARGET KINASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER COMPRISING SAME
US 2024300991 A1
申请人: FUTURE MEDICINE CO LTD
优先权: 2021
CN
EP
US
WO
5 件公开
PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A
EP 4415816 B1
申请人: BIOSPLICE THERAPEUTICS INC
优先权: 2021
EP
US
WO
5 件公开
COMBINATION THERAPY WITH IMMUNOMODULATORS, DYRK1A INHIBITORS, AND GLP1R AGONISTS FOR TYPE 1 DIABETES TREATMENT
EP 4532689 A4
申请人: ICAHN SCHOOL MED MOUNT SINAI
优先权: 2022
CN
EP
US
WO
4 件公开
Suppression of neuroinflammation and composition and method therefor
US 12605368 B2
申请人: UNIV KYOTO
优先权: 2020
CN
EP
US
4 件公开
7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS
EP 4415818 A1
申请人: BIOSPLICE THERAPEUTICS INC
优先权: 2021
EP
US
WO
4 件公开
第 1 / 7 页
上一页
下一页
药物
反馈